141 results about "Lung alveolus" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

The application discloses a lung ventilation-perfusion imaging area image segmentation and quantitative analysis system and relates to the technical field of medical image analysis.The system comprises a data acquisition module, which acquires SPECT V / Q image data and case information corresponding to the SPECT V / Q image data, and generates a structured data set; a feature extraction module, which performs format conversion and multi-scale feature extraction on the SPECT V / Q image data in the structured data set, and generates a compressed feature map data set; a lung lobe segmentation module, which inputs the compressed feature map data set into a U-Net model, segments lung lobe areas, performs post-processing, and generates a lung lobe area mask image; and an image fusion module, which performs alpha blending fusion on the lung lobe area mask image and the SPECT V / Q image data, and generates a color fusion image.The application captures lung alveolus-to-lung lobe structure by fusing four branch features of a hollow pyramid network, and reduces GPU memory consumption.

The invention discloses a formula for reducing phlegm and resolving masses, and a preparation method and application of freeze-dried powder of the formula for reducing phlegm and resolving masses, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition inhibits triple negative breast cancer adhesion-metastasis by regulating an FAK / SRC pathway, and comprises the following components by weight: 10-20 g of poria cocos, 10-20 g of rhizoma bolbostemmae, 10-20 g of radix trichosanthis, 5-12 g of curcuma zedoary, 10-20 g of selfheal, 10-20 g of oyster (smashed and decocted first), and 5-12 g of uniflower swisscentaury root. In-vitro experiments show that HTSJF can inhibit TNBC cell invasion, migration and adhesion (P is less than 0.01) in a dose-dependent manner, and along with reduction of the phosphorylation level of an FAK / SRC pathway, it is prompted that HTSJF inhibits TNBC transfer by regulating the pathway. In-vivo experiments prove that the HTSJF can obviously inhibit the reduction of TNBC pulmonary metastasis focus (P is less than 0.05) and recover part of normal pulmonary alveolar structures, and the inhibition effect of the HTSJF on TNBC pulmonary metastasis is further proved.

The invention provides a compound based on aspergillus oryzae spores. The compound is composed of carbonized aspergillus oryzae spore microsphere surfaces and pores loaded with quercetin. The average porosity of the carbonized aspergillus oryzae spore microspheres is 25%-45%; the mass of the quercetin accounts for 30%-50% of the total mass of the compound. According to the compound, the solubility and bioavailability of quercetin are remarkably improved, efficient pulmonary alveolar deposition is guaranteed through the optimized aerodynamic diameter of the compound, and rapid intake of macrophages is guaranteed through the rough surface of the compound. An in-vivo and in-vitro ALI model verifies the safety of the compound QU-cASP prepared by the invention, and the compound QU-cASP has excellent effects in the aspects of targeted delivery, oxidative stress inhibition and macrophage polarization regulation. The invention also provides a method for preparing the compound, an application of the compound in preparation of a medicine for relieving acute lung injury, and an inhalable preparation taking the compound as an active ingredient.

The invention relates to the technical field of organoid culture, in particular to a pulmonary fibrosis organoid model and a construction method and application thereof. The pulmonary fibrosis organ-like model is obtained by co-culturing lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages. According to the invention, macrophages are innovatively introduced, a ternary co-culture system of lentivirus stably transfected alveolar epithelial cells, human embryonic lung fibroblasts MRC-5 and macrophages is constructed, and a key'epithelial injury-immune infiltration-fibroblast activation 'pathological triangle in a pulmonary fibrosis pathogenesis process can be more comprehensively simulated; the finally obtained pulmonary fibrosis organ-like model provides an efficient tool for pulmonary fibrosis mechanism research and research, development and screening of anti-pulmonary fibrosis drugs.

The invention belongs to the technical field of biology, and relates to a bronchoalveolar lavage fluid (BALF) preserving fluid, a kit and a cytological test method. The preservation solution is composed of TCEP, N-acetylcysteine, EDTA.2Na, trehalose, Proclin300, methanol, sodium chloride and HEPES, and all the components have a synergistic effect to achieve sample viscosity removal, oxidation resistance, corrosion prevention, cell protection and pH stabilization. The preserving fluid is suitable for morphological observation and nucleic acid detection of BALF cells, and can stably preserve samples at room temperature and maintain completeness of cell membranes and clear morphological structure. The kit comprises two preparations which are mixed to form a working solution, and the working solution can be directly used for sample preservation on a sampling site. The cytological test method comprises the steps of sample collection, preservation, centrifugal slide preparation, Wright-Giemsa staining and microscopic observation. Experimental results show that preservation solutions of different formulas are compatible with a chromosome system, the cell morphology is kept stable within 3 days, the dyeing effect is good, and it is proved that the preservation system can remarkably improve the preservation stability and detection reliability of BALF samples and is suitable for cytology and molecular diagnosis application of lower respiratory diseases.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The application discloses a compound containing a 3-alkynyl pyrrole structure and application thereof. The compound containing the 3-alkynyl pyrrole structure provided by the application is confirmed to have a down-regulation effect on inflammatory factors secreted by LPS-induced primary alveolar macrophages through cell experiments, and has no obvious cytotoxicity. The application provides a new treatment strategy for clinical acute lung injury (ALI) treatment.

The invention discloses an application of thermal sensitive Sibestein granules in treating / or preventing asthma, and belongs to the technical field of biological medicines. The invention finds that the thermal sensitive Sibestein granules can reduce the total number of cells and the number of eosinophilic granulocytes, neutrophil granulocytes and lymphocytes in asthma mice BALF, reduce the level of cell factors in asthma mice BALF and IgE in serum, reduce exudation of inflammatory substances in airway and alveolar tissues of asthma mice and infiltration of inflammatory cells, improve the lesion degree of lung tissues, and improve the curative effect of the lung tissues. The action mechanism may be related to regulation and control of MAPK / NF-kappa B signal channel related protein expression, so that inflammatory response and cell apoptosis are inhibited, and airway inflammation of mice is relieved.

The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and / or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.

The invention discloses a method for preparing a VA-ECMO lung injury treatment medicine by using ginkgolide A to regulate YARS1, and relates to the technical field of biological medicine, the method comprises the following steps: by using ginkgolide A as a YARS1 protein regulator, preparing the medicine for treating the VA-ECMO lung injury through virtual screening, binding affinity confirmation and cell efficacy confirmation; wherein the virtual screening is based on a protein structure model of YARS1, and bilobalide A with high affinity binding energy with YARS1 is screened out through molecular docking. It is proved that ginkgolide A can effectively improve the lung ventilation function by regulating YARS1, repair the alveolar epithelial barrier structure and inhibit the inflammatory oxidative stress reaction, and the lung injury treatment effect and clinical transformation safety under the support of VA-ECMO are improved.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention relates to an application of an MYOF protein in preparation of a product for preventing, relieving and / or treating acute lung injury. According to the application, the MYOF protein can be combined with GSDMD-NT, and up-regulation of expression of the MYOF protein can effectively inhibit activation of GSDMD and pyroptosis mediated by GSDMD, so that the MYOF protein has an application prospect in preparation of products for preventing, relieving and / or treating acute lung injury, and the technical problem that alveolar epithelial barriers are easily damaged during treatment can be solved.

The application provides an application of Buyang Huanwu Decoction in the preparation of a product for treating high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and belongs to the technical field of medicines. After the prescription of the Buyang Huanwu Decoction is decocted with water, the decoction is used for treating high altitude pulmonary injury, can reduce pathological injury of lung tissues, reduce thickening of alveolar walls, make lung tissue structure clearer, and close to normal lung tissue morphology; meanwhile, the decoction can enhance exercise capacity, reduce asthenia symptoms of high altitude pulmonary injury of qi deficiency and blood stasis syndrome, and effectively treat high altitude pulmonary injury of qi deficiency and blood stasis syndrome.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The application belongs to the technical field of biological medicine, and particularly relates to the use of a lung extracellular matrix hydrogel in the preparation of a lung injury repair material. The application grafts methacrylic anhydride groups on a lung tissue-derived extracellular matrix, and provides a lung extracellular matrix hydrogel which can be rapidly photo-crosslinked, has high stability, effectively promotes angiogenesis, and prevents postoperative leakage. The photo-crosslinked lung extracellular matrix hydrogel of the application is applied to a lung injury animal model, significantly promotes angiogenesis, promotes alveolar regeneration, and also significantly reduces the fibrosis level. Compared with a sealing agent alpha-cyanopropyl acrylate gel and a fibrin glue which are used in clinical application, the photo-crosslinked lung extracellular matrix hydrogel has excellent effects on repairing lung injury, provides a new strategy for repairing traumatic and iatrogenic lung injury, and has a good application prospect.

The utility model discloses a pulmonary alveolar lavage fluid collecting device for rats and mice, which comprises a lavage needle (100), the lavage needle (100) comprises a needle head (101), a catheter (102) and a tube seat (103) which are sequentially communicated and connected from bottom to top, the outer surface of the needle head (101) is smooth and is used for preventing the tracheal wall from being scratched; the catheter (102) is arranged on the lavage needle (100), the trachea clamp (200) is provided with a reverse fork locking clamp structure, and the trachea clamp (200) is matched with the catheter (102) of the lavage needle (100) and used for stably clamping the catheter (102). By designing the special lavage needle and the trachea clamp, efficient and safe alveolar lavage fluid collection without suture line ligation is realized, the operation process is simplified, the sample quality and the experiment efficiency are improved, and meanwhile, the alveolar lavage fluid collection device can meet the requirements of experimental animals with different sizes.

The utility model discloses an oxygen path detection structure, and belongs to the field of oxygen path detection. An oxygen path detection structure comprises a front shell and a rear shell, and further comprises a first mounting plate fixedly arranged on the front shell, and a flow detection sensor is arranged on the first mounting plate; the second mounting plate is fixedly arranged on the front shell, and a concentration detection sensor is arranged on the second mounting plate; the fixing frame is arranged on the inner side wall of the front shell, and a pressure sensor is arranged in the fixing frame; the air inlet nozzle and the air outlet nozzle are arranged on the two sides of the top of the front shell respectively; according to the utility model, the flow, concentration and pressure of gas in an oxygen path can be detected, oxygen poisoning or hypoxemia of a patient caused by abnormal concentration can be avoided, and the problems of pipeline rupture or alveolar injury caused by overhigh pressure or insufficient oxygen supply caused by overlow pressure can be prevented.

The utility model discloses an electrically-driven multifunctional cardiopulmonary model, relates to the field of teaching models, and particularly aims to solve the problems that in the prior art, in the teaching process of an existing teaching double-lung model, only arteries and other structures and the distribution condition of lung segments can be determined, and the teaching efficiency is low. In order to solve the problems that in the prior art, in the prior art, the whole process of lung gas exchange, lung circulation and alveolar change cannot be further dynamically simulated, and the working process of the heart and the lung cannot be vividly restored, the utility model provides an electrically-driven multifunctional heart and lung model which is scientific and vivid, meets more teaching contents, enables a solid model to be dynamic, enables the lung physiological process to be visualized, and improves the teaching efficiency. The main physiological functions of the lung are simulated through various lights, the basic anatomical structure and the dynamic physiological process are combined, the lung anatomical structure and the physiological functions are comprehensively displayed, the discipline barrier is broken, learning and understanding of students are facilitated, and the higher teaching requirements at present are met.

The present invention relates to a novel method of treating pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency (AATD), a genetic disorder that causes low levels of alpha-1 antitrypsin (AAT), a protein that protects the lungs from damage by neutrophil elastase. The invention consists of aerosolizing nanoparticles composed of apolipoprotein A1 enriched with AAT (A1NP). The invention aims to deliver these nanoparticles directly to the lungs, where they can interact with the alveolar surface and modulate the inflammatory and proteolytic processes that lead to emphysema. In particular, the inventors report that said nanoparticles are not cytotoxic, have anti-inflammatory and anti-elastase properties, can cross alveolar epithelial cells, and are not immunogenic in mice.

The invention belongs to the technical field of biological analysis, and relates to a method for performing mass spectrum imaging analysis on lung tissues and application. In order to solve the problem that the structural integrity is difficult to maintain in the lung tissue freezing and slicing process, a liquid shaping agent is adopted to conduct internal perfusion on fresh lung tissue, the airway and the pulmonary alveoli are filled, and the shaping agent supports the lung tissue to maintain the natural state in the subsequent operation after being solidified at low temperature. The prepared lung tissue frozen section can be used for mass spectrum imaging analysis and research.

The invention belongs to the technical field of biological medicine, provides novel application of PRMT6, and particularly relates to application of a PRMT6 inhibitor in preparation of a medicine for preventing or treating sepsis-ARDS. The invention discloses the application value of the PRMT6 as the sepsis-ARDS treatment target for the first time. According to the application disclosed by the invention, the expression of PRMT6 is inhibited in a targeted manner, ferroptosis in alveolar epithelial cells (AECs) can be effectively inhibited, and the histopathology related to ARDS is further improved, so that the disease progress is effectively improved, and a new path is opened up for targeted therapy of sepsis-ARDS.

The invention belongs to the technical field of micro-fluidic chips, and provides a micro-fluidic lung chip for simulating child lung physiological characteristics, and particularly aims at simulating specific respiratory frequencies of children at different growth stages, simulating a tissue barrier interface of pulmonary epithelium and endothelium, and simulating a fluid microenvironment. The micro-fluidic chip is mainly composed of two layers of micro-channels, the channels are separated by a polydimethylsiloxane porous membrane, two sides of each channel are respectively provided with a vacuum cavity, each layer of channel is provided with an inlet and an outlet, and a dynamic environment is formed through fluid. Lung epithelial cells and endothelial cells are respectively inoculated in the upper channel and the lower channel on the chip to form an alveolar-capillary interface on the chip. By applying negative pressure to the vacuum cavity, the respiratory frequencies of children in different growth stages are simulated. The invention provides a multi-factor participated tissue level research system for children lung diseases and children medicine research.

A method, ventilation system, and ventilation device for assessing lung re-expansion using a controlled ventilation device are disclosed. The method includes: ventilating a subject under first ventilation parameters and acquiring first impedance data; generating a first lung image, wherein each pixel corresponds to one first impedance data; determining a first target region having a preset alveolar opening state based at least on the first impedance data, and obtaining a first evaluation parameter based on the first target region; ventilating the subject under second ventilation parameters for enabling lung re-expansion and acquiring second impedance data; generating a second lung image, wherein each pixel corresponds to one second impedance data; determining a second target region having a preset alveolar opening state based at least on the second impedance data, and obtaining a second evaluation parameter based on the second target region; and obtaining an assessment result of lung re-expansion based on the first and second evaluation parameters. This application achieves an effective assessment of lung re-expansion.

The invention provides application of SPP1 and / or AREG as a biomarker in preparation of a product for evaluating the curative effect of mesenchymal stem cells on alveolar proteinosis, and belongs to the technical field of biological medicine. The invention provides application of SPP1 and / or AREG as a biomarker in preparation of a product for evaluating the curative effect of mesenchymal stem cells on alveolar proteinosis. MSCs and GM-CSF treatment is carried out on aPAP model mice, and it is found that after MSCs treatment, SPP1 is positive, and the proportion of AREG positive macrophage subsets is decreased. Therefore, SPPI and AREG can be used as a biomarker for evaluating the curative effect of aPAP treated by MSC, a novel evaluation index is provided for development of clinical evaluation of the aPAP treatment curative effect, and a new treatment target and a theoretical basis are provided for clinical transformation.

The present invention relates to a composition for inducing the reprogramming of type 1 alveolar cells into type 2 alveolar cells, comprising ML141 as an active ingredient. According to the present invention, by reprogramming AT1 cells into AT2 cells using ML141, it is possible to efficiently secure AT2 cells, which were difficult to obtain in sufficient numbers. Furthermore, it is expected that by reprogramming AT1 cells into AT2 cells within the organoid while culturing the organoid itself rather than culturing a single cell, cells with physiological activity similar to actual tissue can be secured.

The present invention relates to a pathological pulmonary fibrosis model, a construction method therefor, and a use thereof. The pathological pulmonary fibrosis model provided by the present invention has good stability and controllability and high maturity, can better simulate the function and structural characteristics of the alveolar-capillary barrier, and has the pathological characteristics of pulmonary fibrosis lesions and the immune microenvironment. The model has the advantage of high simulation degree, and has good application prospects in the aspects of simulation and research of pulmonary fibrosis diseases, as well as drug detection, screening, assessment, and research and development, and the like.

The invention relates to the technical field of molecular biomedicine, in particular to a method and system for predicting the outcome of an ICU patient based on bronchoalveolar lavage fluid mNGS flora in combination with machine learning. The mNGS detection technology disclosed by the invention comprises the following steps: extracting nucleic acid in pulmonary alveolar lavage fluid, constructing a library, sequencing on a machine, analyzing flora and constructing a machine learning prediction model. According to the invention, a method for accurately predicting the outcome of the ICU patient can be provided clinically.